Citi Maintains Buy On MedAssets (MDAS)

Citi Investment Research is maintaining its Buy on MedAssets, Inc. MDAS, along with its $26 price target. In a note sent to clients, Citi writes, "As a result of its successful completion of Broadlane acquisition, MDAS management will host a conference call on November 30th at 8:00 a.m. EST to discuss its updated financial guidance, including any expected acquisition-related restructuring charges and deferred revenue discounts. We will publish an updated model with any revisions shortly thereafter; maintain Buy, High Risk rating." Shares of MDAS lost 44 cents on Friday to close at $16.71, a loss of 2.5%.